European Notebook: Sanofi, AstraZeneca Seek New Uses For Old R&D Sites
VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.
You may also be interested in...
Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico
Infinity gains street cred with AbbVie partnership on duvelisib, while AbbVie also branches out into aging disease by obtaining a stake in Google’s Calico; Palatin and Gedeon Richter pair up on female sexual dysfunction; and AstraZeneca finds an oncology discovery engine in Redx.
Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.
Sanofi May Get EU Double Whammy After French Fine For Hindering Entry Of Plavix Generics
Echoing the European Commission’s probe into whether drug companies blocked regional entry of cheaper generics, France’s Competition Authority has fined Sanofi €40.6 million for hindering domestic access to generic equivalents of its blockbuster clot-buster Plavix.